UCSF was the fourth-largest recipient of National Institutes of Health (NIH) research dollars in 2004, receiving a total of $438.8 million from all awards in the nationally competitive process, according to new rankings released by NIH. The ranking covers research grants, awards and contracts. UCSF’s School of Dentistry, School of Nursing and School of Pharmacy each ranked first nationally for 2004, as they have in recent years.
A publication in the June issue of the scientific journal Diabetes showed that a 2-week therapy with the drug hOKT3gamma1(Ala-Ala) slows the progression of type 1 diabetes for at least two years after treatment.
For patients with diabetes, their family members and friends, nothing is more frightening than a hypoglycemic or low blood sugar episode. After the episode, many patients feel like they've been "hit by a freight train". Even though clinicians work closely with patients to reduce or eliminate these episodes, occasionally a severe hypoglycemic reaction can occur. Fortunately, thanks to researchers at the UC San Francisco VA Medical Center, a possible therapy may help prevent brain impairment
Most families affected by diabetes recognize that islet transplantation represents a very real opportunity for a cure for diabetes. Unfortunately, current experimental treatment protocols require the use of cadaveric pancreas donors. Tragically, only 300 successful islet transplants have been performed in the U.S.
Are you aware of the following shocking statistics? Nearly 100,000 American men, women and children currently await life-saving transplants, a large percentage of whom have diabetes; Approximately 18,000 Californians are waiting for an organ transplant, nearly 20% of the total number of patients waiting for a transplant -- and a second chance at life; Every 13 minutes another name is added to the national transplant waiting list; An average o
The Diabetes Center’s Dr. Ira Goldfine and his team believe they have identified one of the major proteins causing insulin resistance and type 2 diabetes. In a recent study published in the journal Diabetes, Goldfine reported that mice expressing the human version of the protein PC-1 in their liver have significantly elevated blood glucose levels and show 2-fold higher levels of insulin compared to controls.
At last fall's Annual Meeting of the Western Regional Islet Group, the first newly announced Dr. Gerold M. Grodsky Distinguished Scientist Award and Lectureship was given to none other than its namesake, UCSF's Dr. Gerold M. Grodsky. This annual award was created in recognition of his pioneering and continuing scientific contributions in the areas of islet-cell physiology and insulin secretion.
Last fall, three UCSF professors who are long-time associates of the Diabetes Center both received one of the nation's highest honors in the fields of medicine and health. On Oct. 18, 2004, Fred Cohen, MD, DPhil, Professor of Cellular and Molecular Pharmacology and Arthur Weiss, MD, PhD, Professor of Medicine and Chief of the Division of Rheumatology were elected to the Institute of Medicine (IOM) of the National Academies.
A new tool that gives researchers the ability to block disease-causing genes is the next wave in biotechnology. If successful, “RNA interference” (known as RNAi) could provide new cures for everything from cancer to HIV to diabetes. Dr. Michael McManus, a world leader in RNAi, recently moved his MIT laboratory to the Diabetes Center at UCSF to focus his groundbreaking research on the problem of diabetes.
The body's rejection of transplanted organs and tissues is an unfortunate risk of transplant surgery. Historically, rejection rates in a simultaneous pancreas-kidney (SPK) transplant have been as high as 80% and, in 2001, averaged nearly 20% . What's more, steroid-based immunosuppressive drugs that have been traditionally used to combat rejection are associated with several serious side-effects, including increased risks of osteoporosis and bone and joint problems.
Information on clinical trials conducted by Diabetes Center at UCSF researchers is now available online through the Diabetes Center website. Users can access an up-to-date list of UCSF clinical trials in type 1 and type 2 diabetes that are seeking to enroll patients, with information on each trial as well as study contacts to find out more about eligibility and enrollment.